Platelet-derived sphingosine 1-phosphate induces migration of Jurkat T cells

Lipids in Health and Disease

Volumn 13, Issue 1, 2014, Pages

  Iino, Junko ^a,c   Osada, Makoto ^d   Kurano, Makoto ^a,b   Kaneko, Makoto ^a,b   Ohkawa, Ryunosuke ^c   Satoh, Yumiko ^a   Okubo, Shigeo ^a   Ozaki, Yukio ^d   Tozuka, Minoru ^c   Tsuno, Nelson H ^e   Yatomi, Yutaka ^a,b  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d UNIVERSITY OF YAMANASHI   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

Jurkat T cells; Lymphocytes; Migration; Platelets; Sphingosine 1 phosphate

Indexed keywords

2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; LYSOPHOSPHATIDIC ACID RECEPTOR; PERTUSSIS TOXIN; PHOSPHOLIPID; SPHINGOSINE 1 PHOSPHATE; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE 1-PHOSPHATE;

ADULT; ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CELL SEPARATION; CELL STIMULATION; CONTROLLED STUDY; ENZYMATIC ASSAY; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; JURKAT CELL LINE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPERNATANT; T LYMPHOCYTE; THROMBOCYTE ACTIVATION; ANALOGS AND DERIVATIVES; CELL COMMUNICATION; CELL MOTION; METABOLISM; PHYSIOLOGY; THROMBOCYTE;

BLOOD PLATELETS; CELL COMMUNICATION; CELL MOVEMENT; HUMANS; JURKAT CELLS; LYSOPHOSPHOLIPIDS; RECEPTORS, LYSOPHOSPHATIDIC ACID; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 84908012446     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-13-150     Document Type: Article

References (28)

1. Principles of bioactive lipid signalling: lessons from sphingolipids. Hannun YA, Obeid LM, Nat Rev Mol Cell Biol 2008 9 139 150 10.1038/nrm2329 18216770
2. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group, N Engl J Med 2010 362 402 415 10.1056/NEJMoa0907839 20089954
3. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P, FREEDOMS Study Group, N Engl J Med 2010 362 387 401 10.1056/NEJMoa0909494 20089952
4. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, Parikh NS, Habrukowich C, Hla T, Circ Res 2008 102 669 676 10.1161/CIRCRESAHA.107.165845 18258856
5. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Pappu R, Schwab SR, Cornelissen I, Pereira JP, Regard JB, Xu Y, Camerer E, Zheng YW, Huang Y, Cyster JG, Coughlin SR, Science 2007 316 295 298 10.1126/science.1139221 17363629
6. Erythrocytes store and release sphingosine 1-phosphate in blood. Hänel P, Andréani P, Gräler MH, FASEB J 2007 21 1202 1209 10.1096/fj.06-7433com 17215483
7. Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters. Ohkawa R, Nakamura K, Okubo S, Hosogaya S, Ozaki Y, Tozuka M, Osima N, Yokota H, Ikeda H, Yatomi Y, Ann Clin Biochem 2008 45 356 363 10.1258/acb.2007.007189 18583619
8. Sphingosine 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. Yatomi Y, Igarashi Y, Yang L, Hisano N, Qi R, Asazuma N, Satoh K, Ozaki Y, Kume S, J Biochem 1997 121 969 973 10.1093/oxfordjournals.jbchem.a021681 9192741
9. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Yatomi Y, Ohmori T, Rile G, Kazama F, Okamoto H, Sano T, Satoh K, Kume S, Tigyi G, Igarashi Y, Ozaki Y, Blood 2000 96 3431 3438 11071638
10. Immune mechanisms in atherosclerosis. Hansson GK, Arterioscler Thromb Vasc Biol 2001 21 1876 1890 10.1161/hq1201.100220 11742859
11. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Tedgui A, Mallat Z, Physiol Rev 2006 86 515 581 10.1152/physrev.00024.2005 16601268
12. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Zhou X, Nicoletti A, Elhage R, Hansson GK, Circulation 2000 102 2919 2922 10.1161/01.CIR.102.24.2919 11113040
13. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis. Zhou X, Robertson AK, Rudling M, Parini P, Hansson GK, Circ Res 2005 96 427 434 10.1161/01.RES.0000156889.22364.f1 15662027
14. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. Gräler MH, Goetzl EJ, FASEB J 2004 18 551 553 14715694
15. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. Ulrych T, Böhm A, Polzin A, Daum G, Nüsing RM, Geisslinger G, Hohlfeld T, Schrör K, Rauch BH, J Thromb Haemost 2011 9 790 798 10.1111/j.1538-7836.2011.04194.x 21251196
16. T cells in atherosclerosis. Tse K, Tse H, Sidney J, Sette A, Ley K, Int Immunol 2013 25 615 622 10.1093/intimm/dxt043 24154816
17. Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. Graeler M, Shankar G, Goetzl EJ, J Immunol 2002 169 4084 4087 10.4049/jimmunol.169.8.4084 12370333
18. Platelets an inflammatory force in transplantation. Morrell CN, Sun H, Swaim AM, Baldwin WM, Am J Transplant 2007 7 2447 2454 10.1111/j.1600-6143.2007.01958.x 17927608
19. Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus. Nagahama M, Nomura S, Ozaki Y, Yoshimura C, Kagawa H, Fukuhara S, Autoimmunity 2001 33 85 94 10.3109/08916930108995993 11264787
20. Relationships between platelets and inflammatory markers in rheumatoid arthritis. Milovanovic M, Nilsson E, Järemo P, Clin Chim Acta 2004 343 237 240 10.1016/j.cccn.2003.12.030 15115702
21. In vivo imaging in mice reveals local cell dynamics and inflammation in obese adipose tissue. Nishimura S, Manabe I, Nagasaki M, Seo K, Yamashita H, Hosoya Y, Ohsugi M, Tobe K, Kadowaki T, Nagai R, Sugiura S, J Clin Invest 2008 118 710 721 18202748
22. Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass. Zahler S, Massoudy P, Hartl H, Hähnel C, Meisner H, Becker BF, Cardiovasc Res 1999 41 722 730 10.1016/S0008-6363(98)00229-6 10435044
23. Oral FTY720 administration induces immune tolerance and inhibits early development of atherosclerosis in apolipoprotein E-deficient mice. Huang K, Li SQ, Wang WJ, Liu LS, Jiang YG, Feng PN, Wang YQ, Wang SM, Int J Immunopathol Pharmacol 2012 25 397 406 22697071
24. The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Keul P, Tölle M, Lucke S, von Wnuck Lipinski K, Heusch G, Schuchardt M, van der Giet M, Levkau B, Arterioscler Thromb Vasc Biol 2007 27 607 613 10.1161/01.ATV.0000254679.42583.88 17158351
25. FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, Brinkmann V, van Berkel T, Assmann G, Biessen EA, Circulation 2007 115 501 508 10.1161/CIRCULATIONAHA.106.641407 17242282
26. Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets. Yatomi Y, Ruan F, Hakomori S, Igarashi Y, Blood 1995 86 193 202 7795224
27. Plasma sphingosine 1-phosphate metabolism and analysis. Yatomi Y, Biochim Biophys Acta 2008 1780 606 611 10.1016/j.bbagen.2007.10.006 17980708
28. A novel colorimetric assay for the determination of lysophosphatidic acid in plasma using an enzymatic cycling method. Kishimoto T, Matsuoka T, Imamura S, Mizuno K, Clin Chim Acta 2003 333 59 67 10.1016/S0009-8981(03)00165-7 12809736